Company profile
Lineage Cell Therapeutics, Inc.
AMEX:LCTXBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06841770 | phase1 | recruiting | 2025-06-30 | 2027-08-10 | Lineage Cell Therapeutics, Inc. | A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury |
| NCT02302157 | phase1_2 | completed | 2015-03-01 | 2018-12-01 | Lineage Cell Therapeutics, Inc. | Dose Escalation Study of AST-OPC1 in Spinal Cord Injury |
| NCT01217008 | phase1 | completed | 2010-10-01 | 2013-07-01 | Lineage Cell Therapeutics, Inc. | Safety Study of GRNOPC1 in Spinal Cord Injury |
FDA applications (0)
No records yet.